News

Pfizer pacing for 4th day of gains
Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...
Pfizer: Better To Face The Harsh Reality Than Continue Waiting
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer Stock Is Trading Higher Tuesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.
Fierce Biotech19h
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
Stock Movers: Home Depot, 3SBio-Pfizer, UNH
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Pfizer scientist claimed COVID vax results being delayed until after 2020 election ‘wasn’t a coincidence’: House GOP panel
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.
Explore more
PharmExec10h
Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
BioSpace16h
Pfizer Puts $6B on the Line For 3SBio’s PD-1/VEGF Antibody
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
Pfizer share price rises 13% post Q4 Results, dividend announcement despite stock Market crash: Do you own?
Pfizer share price gained 13% in the intraday trades on Tuesday post Q4 Results, dividend announcement and despite stock ...